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Abstract We previously showed that the neuroendocrine pol- 
ypeptide 7B2 transiently interacts with prohormone convertase 
PC2 in the secretory pathway of neuroendocrine cells. Here we 
demonstrate that the processed, but not the intact, form of 7B2 
can enhance the in vitro cleavage of newly synthesized pro- 
hormone proopiomelanocortin (POMC) in lysates of Xenopus 
intermediate pituitary cells. PC2 is presumably the cleavage n- 
zyme involved since intact 7B2 abolishes the nhancing effect of 
processed 7B2 and is known to act as a specific inhibitor of PC2. 
Furthermore, processed 7B2 stimulates in vitro POMC cleavage 
by immunopurified Xenopus PC2. Our results indicate that 7B2 
can display chaperone activity towards PC2. 
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found that the intact form of 7B2 interacts with proPC2 in the 
ER and Golgi region of Xenopus and mouse intermediate pitu- 
itary cells ([17], J.A.M. Braks and G.J.M. Martens, unpub- 
lished results). Based on its functional characteristics and the 
finding that the N-terminal half of 7B2 is distantly related to 
members of the Hsp60 family of chaperones, 7B2 has been 
referred to as a neuroendocrine chaperone [17]. In vitro, the 
recombinant intact form of 7B2 (and not its processed form) 
inhibits PC2 convertase activity and blocks autocatalytic con- 
version of proPC2 into its mature form [24,25]. These observa- 
tions indicate that intact 7B2 regulates PC2 activity in neuro- 
endocrine cells by preventing premature proPC2 conversion. 
Here we report that the N-terminal processed form of 7B2 
enhances in vitro cleavage of newly synthesized proopiomela- 
nocortin (POMC) by Xenopus PC2. 
1. Introduction 
The prohormone convertases PC1 (also referred to as PC3) 
and PC2 are responsible for proteolytic leavage of pro- 
hormones and neuropeptide precursors at pairs of basic amino 
acids [1-2]. The activity of these subtilisin-like enzymes in the 
secretory pathway of neuroendocrine cells is regulated at mul- 
tiple levels. PC1 and PC2 exhibit an acidic pH optimum and 
Ca 2+ dependence which limits their activity mainly to the trans- 
Golgi network (TGN) and the secretory granules [3-6]. Fur- 
thermore, PC1 and PC2 are synthesized as proenzymes and 
their activation i volves proteolytic removal of the N-terminal 
proregion, a process that is thought o be autocatalytic [7-9]. 
The conversion of proPC1 to PC1 has been demonstrated to 
occur in the endoplasmic reticulum (ER) [10-12] whereas mat- 
uration of proPC2 was shown to take place only in the later 
compartments of the secretory pathway [13 14]. The delayed 
maturation of proPC2 is consistent with the fact that PC2 is 
involved in the later steps of prohormone cleavage [15-16]. 
Recently we proposed that activation of proPC2 is regulated 
by the neuroendocrine polypeptide 7B2 [17]. Like PC2, the 7B2 
protein is present in the secretory pathway of a wide variety of 
neural and endocrine cells [18-21]. 7B2 is synthesized as a 
25-29-kDa protein that is C-terminally processed in the TGN, 
resulting in an 18-21-kDa secretory product [22-23]. We have 
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Abbreviations: PC1 and PC2, prohormone convertase 1 and 2; ER, 
endoplasmic reticulurn; TGN, trans-Golgi network; POMC, proopio- 
melanocortin; MSH, melanophore stimulating hormone; ACTH, 
adrenocorticotropic hormone; PAGE, polyacrylamide g l electropho- 
resis; SDS, sodium dodecyl sulphate; MES, 4-morpholineethanesulfo- 
nic acid. 
2. Materials and methods 
2.1. Recombinant 7B2 proteins 
The prokaryotic expression constructs encoding normal a d mutated 
forms of 7B2 were generated with synthetic primers and PCR [25]. 
Production and purification of the recombinant proteins was per- 
formed as described previously [24]. Recombinant intact 7B2 (amino 
acid residues 1-185; numbering refers to [26]), pr cessed 7B2 (residues 
1-151), the C-terminally truncated 7B2 mutants pNK171 (1-171), 
pNF177 (1-177), pNG162 (1-162), pNP131 (1 ), and pNG86 (1 
86), and the N-terminally truncated 7B2 mutants pCP93 (93-185) and 
pCD125 (125-185) were us d in the present study. 
2.2. Radiolabeling of Xenopus intermediate pituitaries and preparation 
of tissue lysates 
Intermediate pituitaries were dissected from black adapted Xenopus 
laevis and radiolabeled with Tran[35S] label (ICN Radiochemicals) as 
described previously [17]. Pulse labeling was performed for 2 h in the 
presence of brefeldin A (2.5 pg/ml, Sigma) and the pituitaries were 
homogenized in lysis buffer (10 mM Hepes, pH 7.2; 140 mM NaC1; 
0.1% Triton X-100; 0.1% sodium deoxycholate; 1% Tween-20; 1 mM 
EDTA; 1 mM phenylmethylsulfonylfluoride; 0.1 mg/ml soybean tryp- 
sin inhibitor). The lysates were cleared by centrifugation (10,000 ×g, 7 
min). 
2.3. Immunopurification of Xenopus PC2 
Intermediate pituitaries of black-adapted Xenopus were dissected, 
homogenized in lysis buffer containing 2 mM EDTA and cleared by 
centrifugation. Polyclonal anti-PC2 antiserum (4BF [13], kindly pro- 
vided by Dr. Iris Lindberg, New Orleans, LA, USA) was added and 
incubation was performed for 2 h at 4°C. Immune complexes were 
collected with protein A-Sepharose and the precipitates were rinsed 
three times in lysis buffer with 2 mM EDTA and once in lysis buffer 
without EDTA. Immunopurified PC2 was used when still attached to 
protein A-Sepharose. 
2.4. POMC cleavage experiments 
For POMC cleavage experiments, radiolabeled Xenopus intermediate 
pituitary lysate was diluted 15 times in assay buffer (50 mM MES, pH 
6.4; 140 mM NaC1; 3 mM Ca2*; 0.02% bovine serum albumin). Samples 
(30 pl, equivalents of~0.05 intermediate pituitary) were incubated for 
the indicated periods of time (usually 4 h) at 24°C in the presence or 
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absence of 0.5 ¢tg recombinant 7B2 (~ 1/.tM final concentration, unless 
otherwise indicated). In some xperiments, ACTH 1-39 (2.5 J/g) or EDTA 
(5 mM final concentration) was present during the incubations. Sam- 
ples were analyzed by SDS-PAGE [27]. When newly synthesized inter- 
mediate pituitary proteins were used as a source of radiolabeled POMC, 
the lysates were heated for 5 min at 90°C. The sample was diluted in 
assay buffer as described for the non-heated lysate and incubations 
were performed at 24°C in the presence or absence of recombinant 7B2 
for 4 h. In some experiments, non-radiolabeled tissue lysate ( quiva- 
lents of ~0.15 Xenopus or mouse intermediate or anterior pituitary), 
prepared by homogenization in lysis buffer, or immunopurified PC2 
(purified from an equivalent of~ 0.4 intermediate pituitary) was present 
during the incubation. 
3. Results 
3.1. Effect of  recombinant 7B2 on POMC conversion in 
Xenopus intermediate pituitary lysate 
After pulse labeling of Xenopus intermediate pituitaries with 
Tran[3SS] label, the main radiolabeled protein in the tissue lysate 
is the prohormone POMC. When a fresh radiolabeled lysate 
was incubated at 24°C under conditions corresponding to the 
TGN (pH 6.4/3 mM Ca2+), only a small amount of 37-kDa 
newly synthesized POMC was converted to lower molecular 
weight products of 30 kDa and 19 20 kDa (Fig. 1A, lane 1). 
However, when the recombinant processed form of 7B2 (resi- 
dues 1-151, ~ 1/zM) was present during the in vitro incubation, 
most of 37-kDa POMC was converted into the 19-20 kDa 
protein. In addition, the 30-kDa protein and a series of proteins 
with sizes between 13 and 18 kDa were generated (Fig. 1A, lane 
2). Other radiolabeled proteins were not affected during the 
incubations. In the presence of 10 times less processed 7B2 (~ 100 
nM) POMC cleavage was still enhanced, although to a lesser 
extent (~30%) (Fig. 1A, lane 3). No stimulation of POMC con- 
version was observed us ing-  10 nM of processed 7B2 (Fig. 1A, 
lane 4). Incubation of the lysate in the presence of intact 7B2 
(residues 1 185, ~ 1/.tM) inhibited rather than enhanced POMC 
conversion, since virtually no 30-kDa and 19-kDa products 
were formed (Fig. 1A, lane 5). A 10-fold lower concentration 
of intact 7B2 (~ 100 nM) still prevented POMC cleavage (Fig. 
1A, lane 6). Intact 7B2 has been shown to act as a specific 
inhibitor of prohormone convertase PC2 in an in vitro enzyme 
assay [24]. Incubation of the lysate in the presence of both 
processed and intact 7B2 (both a t -  1 pM) also led to a complete 
block of POMC conversion, indicating that the intact form of 







1 2 3 4 5 6 7 8 9 10 11 12 13 14 
















i7B2 . . . .  1 o.1 o.oi 1 o.1 O.Ol . . . .  
E H A A 
Fig. 1. Effects of recombinant 7B2 proteins on POMC cleavage in Xenopus intermediate pituitary lysates. Newly synthesized proteins produced by 
Xenopus intermediate pituitaries were incubated for 4 h and analyzed by SDS-PAGE. (A) Incubations were performed in the absence of 7B2 (lane 
1) or in the presence of 1 ¢tM (lane 2), 0.1 ¢tM (lane 3), 0.01 pM (lane 4) recombinant processed 7B2 (p7B2, residues 1-151), in the presence of 1 
pM (lane 5), 0.1 ¢tM (lane 6), 0.01/tM (lane 7) recombinant i tact 7B2 (i7B2, residues 1-185), or in the presence of both 1/IM p7B2 and 1 pM (lane 
8), 0.1 ¢tM (lane 9), 0.01 pM (lane 10) i7B2. In addition, incubations were performed in the presence of 1 ¢zM p7B2 and 5 mM EDTA (lane 11), 
1 ,uM heat-treated p7B2, 0.1 ¢tg/pl ACTH in the absence (lane 13) or presence (lane 14) of 1 ,uM p7B2. (B) Lysates were not incubated (lane 1), 
incubated inthe absence of 7B2 (lane 2), in the presence of i7B2 (lane 3), or in the presence of recombinant truncated forms of 7B2, pNF 177 (residues 
1-177; lane 4), pNK171 (residues 1-171; lane 5), pNG162 (lane 6), p7B2 (lane 7), pNG86 (residues 1 86; lane 8), pCP93 (residues 93-185; lane 9), 
or pCD125 (residues 125-185; lane 10). 
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Fig. 2. Analysis of the effect of processed 7B2 on POMC conversion 
in Xenopus intermediate pituitary lysates. (A) Time course of POMC 
conversion. Newly synthesized proteins produced by Xenopus interme- 
diate pituitaries were extracted (lane 1) dincubated for 0 min (lane 
2), 15 min (lane 3), 1 h (lane 4), 4 h (lane 5), or 20 h (lane 6) in the 
presence of 1 ,uM processed 7B2 (p7B2) and analyzed by SDS-PAGE. 
(B) POMC cleavage products generated in vivo and in vitro. Newly 
synthesized proteins produced by Xenopus intermediate pituitaries after 
a 2-h pulse were xtracted and analyzed by SDS-PAGE (lane 1). Newly 
synthesized proteins were extracted and directly analyzed (lane 2) or 
incubated for 4 h in the presence of 1 HM p7B2 (lane 3). Lane 4, 
molecular weight marker proteins. 
(Fig. 1A, lane 8). Even when processed 7B2 was present in a 
10-fold excess to intact 7B2, the conversion was completely 
blocked (Fig. 1A, lane 9). 
Cleavage of POMC in the presence of the processed form of 
7B2 was partially blocked by EDTA (Fig. 1A, lane 11), an agent 
known to inhibit many proteolytic enzymes, including PC2 [3]. 
Boiling of processed 7B2 did not affect its potency to enhance 
POMC cleavage (Fig. 1A, lane 12), indicating that 7B2 is heat- 
resistant. The fact that the dibasic-site containing peptide 
ACTH (adrenocorticotropic hormone) served as a competing 
substrate for POMC and inhibited 7B2-enhanced POMC con- 
version (Fig. 1A, lanes 13-14) suggests that POMC is cleaved 
at pairs of basic amino acids. 
Subsequently, we examined the effects of a number of mutant 
forms of recombinant 7B2 on POMC conversion. The C-termi- 
nally truncated 7B2 mutant pNF177 (residues 1-177) and the 
N-terminally truncated 7B2 mutants pCP93 (residues 93 185) 
and pCD125 (residues 125-185) inhibited POMC cleavage to 
a degree similar to that of intact 7B2 (Fig. 1B, lanes 34 ,  9-10). 
On the contrary, mutants pNK171 (residues 1-171), pNGI62 
(residues 1-162), and the short mutant pNG86 (residues 1-86) 
hardly affected POMC conversion (Fig. 1B, lanes 5, 6 and 8). 
7B2 mutant pNP131 (residues 1 131) was the only mutant 
having an enhancing effect on POMC cleavage similar to that 
of processed 7B2 (Fig. 1B, lane 7 and data not shown). The 
experiments with the mutants how that the C-terminal region 
of 7B2 is able to inhibit POMC conversion, whereas an N- 
terminal fragment lacking this region can stimulate POMC 
cleavage activity in the lysate. 
3.2. Analys& of POMC conversion 
A time course of 7B2-mediated POMC conversion in the 
Xenopus intermediate pituitary lysate shows a gradual decrease 
in the amount of 37-kDa POMC and the appearance of a set 
of smaller proteins ranging in size from 10 to 30 kDa (Fig. 2A). 
The larger cleavage products gradually disappeared after 
longer incubations and a set of proteins ranging in size from 
10 to 16 kDa were generated. In the absence of processed 7B2, 
hardly any POMC conversion occurred uring a 4-h incubation 
(see Fig. 1A, lane 2). When the lysate was incubated at 24°C 
for 1 h before the addition of processed 7B2, POMC was 
cleaved to the same extent as without the preincubation step 
(data not shown). This indicates that under the assay conditions 
the potency of 7B2 to stimulate POMC cleavage is not affected 
for at least 1 h. The POMC-derived proteins produced in vivo 
are slightly smaller (-  1-2 kDa) than the in vitro generated cleav- 
age products (Fig. 2B, lanes 1 and 3), presumably as a result 
of additional in vivo processing through carboxypeptidases. 
3.3. Effect of recombinant 7B2 on POMC conversion by 
different tissue lysates and by immunopurified Xenopus 
PC2 
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Fig. 3. Effect of processed and intact 7B2 on POMC conversion by 
different lysates and immunopurified Xenopus PC2. Newly synthesized 
proteins produced by Xenopus intermediate pituitaries were heat- 
treated and incubated for 4 h in the absence (lane 1) or presence (lane 
2) of processed 7B2 (p7B2), with fresh non-labeled lysate of Xenopus 
intermediate pituitaries in the absence (lane 3) or presence of 1 tiM 
p7B2 (lane 4) or 1 ,uM intact 7B2 (i7B2, lane 5), with lysates of mouse 
intermediate pituitaries in the absence (lane 6) or presence of 1 tiM 
p7B2 (lane 7) or 1 HM i7B2 (lane 8), and with immunopurified Xenopus 
PC2 in the absence (lane 9) or presence of 1 HM p7B2 (lane 10) or 1 
HM i7B2 (lane 11). Proteins were analyzed b  SDS-PAGE. 
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itary lysate was irreversibly blocked by heating the lysate for 
5 min at 90°C (Fig. 3, lane 1). Addition of only processed 7B2 
to the heat-treated lysate did not result in prohormone conver- 
sion (Fig. 3, lane 2), showing that 7B2 itself is not able to cleave 
POMC. We therefore could use the heat-treated lysate to test 
POMC cleavage activity in other tissue lysates. Addition of 
fresh, unlabeled Xenopus intermediate pituitary lysate to the 
heat-treated radiolabeled proteins, led to some conversion of 
POMC (Fig. 3, lane 3). This conversion was greatly enhanced 
by processed 7B2 (Fig. 3, lane 4) and completely blocked by 
intact 7B2 (Fig. 3, lane 5). Similar results were obtained when 
Xenopus anterior pituitary lysate was used instead of intermedi- 
ate pituitary lysate (data not shown). Incubations of lysates of 
Xenopus brain or heart with the heat-treated radiolabeled lysate 
did not lead to any POMC conversion (data not shown). To- 
gether, these results indicate that the enzyme responsible for 
POMC cleavage is enriched in Xenopus pituitary. 
To examine whether neuroendocrine lysates from other spe- 
cies also possess 7B2-inducible POMC cleavage activity, mouse 
intermediate pituitary lysate was added to the heat-treated radi- 
olabeled Xenopus lysate. In the presence as well as in the ab- 
sence of processed 7B2, considerable conversion of POMC 
occurred (Fig. 3, lanes 6 and 7). This conversion could be 
blocked by intact 7B2 (Fig. 3, lane 8). When diluted mouse 
lysate was used, the extent of POMC cleavage was less, but also 
under these conditions no enhancing effect by processed 7B2 
was observed (data not shown). Thus, the effect of processed 
7B2 on prohormone cleavage appeared to be species pecific. 
To show that PC2 represents he POMC-cleaving enzyme in 
these experiments, PC2 was immunopurified from Xenopus in- 
termediate pituitaries and the immunoisolated PC2 was incu- 
bated with heat-treated radiolabeled lysate. Addition of puri- 
fied PC2 alone did not result in POMC conversion (Fig. 3, lane 
9) but when processed 7B2 was included, POMC was partially 
cleaved into smaller products with the same sizes as those 
produced with the intermediate pituitary lysate (Fig. 3, lane 10). 
4. Discussion 
In the present study, we investigated the effect of recombi- 
nant 7B2 on the in vitro processing of POMC. The intact form 
and several mutants of 7B2 (i.e. pNF 177, pCP93 and pCD 125) 
blocked POMC conversion; these 7B2 forms have previously 
been demonstrated to act as specific inhibitors of PC2 activity 
in in vitro enzyme assays [24--25]. Surprisingly, the processed 
form of 7B2 had a strong enhancing effect on POMC cleavage 
and caused conversion of newly synthesized 37-kDa POMC 
into a number of 10-30 kDa proteins in a dose-dependent 
manner. Incubations with truncated forms of 7B2 revealed that 
a region between residues 86 and 131 is critical for the enhanc- 
ing effect and that the presence of the 7B2 region between 
residues 151 and 162 abolishes the ability of 7B2 to enhance 
POMC processing. 
The experiments with heat-treated lysate indicate that not 
7B2 itself, but a component of the intermediate pituitary lysate 
is responsible for POMC cleavage. Several observations suggest 
that the responsible component in the lysate is the prohormone 
convertase PC2. First, the PC2-blocking agent EDTA and the 
PC2 substrate ACTH had an inhibitory effect on the enhanced 
POMC conversion. Second, only lysates of tissues that are 
known to produce considerable amounts of PC2, like Xenopus 
intermediate and anterior pituitaries, showed 7B2-inducible 
POMC processing. Third, the enhanced conversion of POMC 
by processed 7B2 was completely abolished when intact 7B2, 
a specific PC2-inhibitor, was present during the incubation. 
Fourth, in the presence of processed 7B2, immunopurified 
Xenopus PC2 was able to cleave newly synthesized POMC. 
Since 7B2 is known to interact with PC2 and not with POMC 
[17], the enhancing effect of processed 7B2 on POMC conver- 
sion presumably results from activation of PC2 rather than an 
effect on POMC. Processed 7B2 was found to enhance POMC 
cleavage in Xenopus, but not in mouse pituitary lysate, indicat- 
ing that the characteristics of PC2 differ between the two spe- 
cies. Possibly, in the mouse lysate, PC2 is already present in an 
active form, whereas in the Xenopus lysate the enzyme is virtu- 
ally inactive and apparently needs processed 7B2 to become 
active. Also in our in vitro enzyme assays, processed 7B2 did 
not have any effect on mouse or rat PC2 activity [25]. 
Concerning the mechanism underlying the effect of proc- 
essed 7B2 on POMC processing by Xenopus PC2, several pos- 
sibilities hould be considered. Since the N-terminal half of 7B2 
(amino acids 1-95) is distantly related to a subclass of molecu- 
lar chaperones [17], this region of 7B2 might be involved in 
protein-protein interactions and as such may affect the confor- 
mation of its substrate PC2. In the Xenopus lysate, PC2 may 
be present in a misfolded state or as a folding intermediate, and 
processed 7B2 could then assist in its proper folding or prevent 
its aggregation. The enhancing effect of processed 7B2 on PC2 
activity could also arise from an interaction of 7B2 with the 
proregion of PC2 rather than with the mature nzyme. For the 
propeptides of subtilisin and c~-lytic protease it has been shown 
that they can function as strong competitive inhibitors of their 
respective enzymes [28-29]. If the proregion of PC2 has a sim- 
ilar effect, release of the propeptide from the mature enzyme 
is required for its activation and this process may be mediated 
by 7B2. Using an in vitro binding assay, we previously showed 
that processed 7B2 associates with proPC2, but not with ma- 
ture PC2 [17], indicating that processed 7B2 is indeed able to 
interact with the proregion of proPC2. Interestingly, Zhu and 
Lindberg recently demonstrated that the processed form of 7B2 
facilitates production of enzymatically active PC2 in trans- 
fected cell lines [30]. Collectively, the results indicate that the 
N-terminal portion of 7B2 might well act as a chaperone for 
PC2. 
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